Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sch-900776. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 20/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 18/20 | 1.00 |
| ▸ | CDK2 | P24941 | 18/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 18/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 1/20 | 1.00 |
| ▸ | PRKCI | P41743 | 1/20 | 1.00 |
| ▸ | PSMC4 | P43686 | 1/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sch-900776 SCHEMBL10380123 | 1.00 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| Sch-900776 SCHEMBL17466881 | 1.00 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11930860 | 0.94 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL12404165 | 0.94 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11930994 | 0.92 | CHEK1 (0.88) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL26799847 | 0.90 | CHEK1 (0.81) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11931197 | 0.89 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11935124 | 0.89 | CHEK1 (0.81) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11930955 | 0.89 | CHEK1 (0.79) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL26799831 | 0.89 | CHEK1 (0.79) | CHEK1CCNA2CDK2CCNA1RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 835 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| WO-2025217307-A1 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-12404332-B2 | Methods for diagnosing and treating cancers | RESEARCH DEVELOPMENT FOUNDATION (US) | 2025-09-02 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| CN-115066499-A | Culture system for efficient production of gene transfer vectors | 格雷菲克斯公司 | 2022-09-16 | — | — | CN | claimed |
| US-20220249489-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-08-11 | — | — | US | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-20220211783-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | TRINITY CAPITAL INC., AS AGENT | 2022-07-07 | — | — | US | claimed |
| CN-110585435-B | Composition with anticancer effect and application thereof | 香港浸会大学深圳研究院 | 2022-04-01 | — | — | CN | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3955943-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | Candel Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| US-20160252530-A1 | AGENT FOR PREVENTING OR TREATING SPINOCEREBELLAR ATAXIA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2016-09-01 | — | — | US | claimed |
| EP-3056210-A1 | DRUG FOR PREVENTION OR TREATMENT OF SPINOCEREBELLAR DEGENERATION | National University Corporation Tokyo Medical and Dental University (JP) | 2016-08-17 | — | — | EP | claimed |
| EP-2755482-B1 | COMBINATION OF MK-1775 AND MK-8776 FOR TREATING CANCER | MERCK SHARP & DOHME (US) | 2016-06-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249489-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | CHEK1, CHEK2, ATR | CHEK1 1/4885CCNA2 349/4885CDK2 44/4885 |
| US-12404332-B2 | Methods for diagnosing and treating cancers | CHEK1, CHEK2, MRE11 | CHEK1 1/4885CCNA2 1829/4885CDK2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.